Phase 1 N=226 Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
Poliomyelitis
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=843 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001
Phase 3 N=400 Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9
Primary: Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV — 98.9; 100.0; 98.3; 99.5…
Phase 4 N=215 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Pertussis · Diphtheria · Tetanus
Primary: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination With Either REPEVAX® or COVAXIS® Vaccine — 89; 87; 85; 87 Participants
Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants
Phase 1 N=25 Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
Poliomyelitis
Primary: Number of Subjects Reporting Solicited Local Symptoms — 1; 0; 2; 0 Participants
Phase 3 N=1,183 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
Meningitis, Meningococcal
Primary: Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With…
Phase 3 N=750 Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
Poliomyelitis
Primary: Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity — 187; 179; 175; 149 Participants
Phase 4 N=156 Vaccinating Children After Chemotherapy
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Phase 4 N=400 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia
Poliomyelitis
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 114; 7; 258; 12 Subjects
Phase 3 N=1,660 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Meningococcal Infections
Primary: Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y — 131; 189; 565; 120 Titer
Phase 4 N=211 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
Acellular Pertussis · Poliomyelitis · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens — 61; 66; 68; 63 Subjects